The Consorci Institut D'Investigacions Biomediques August Pi i Sunyer (IDIBAPS) is a premier public research center dedicated to translational research in the field of biomedicine. Its mission is to combine clinical research of proven quality with high-level basic research. Founded in 1996, IDIBAPS is comprised of the Catalan Ministry of Economy and Knowledge (DEC), the University of Barcelona's Faculty of Medicine (UB), the Hospital Clínic i Provincial de Barcelona (HCPB) and the Institut d'Investigacions Biomèdiques de Barcelona of the Spanish Council for Scientific Research (IIBB-CSIC). In 2011, IDIBAPS published a total of 906 original articles in international journals, with a global impact factor of 4,725.06.
IDIBAPS is ideally situated in central Barcelona, a thriving melting pot of 1.62+ million inhabitants boasting a multiplicity of ethnicities and nationalities. IDIBAPS is located at the Clinic Campus (Barcelona, Spain), which is also home to the School of Medicine (University of Barcelona) and the Hospital Clinic of Barcelona. This confluence of teaching hospital and research center has created a rich and powerful synergy and facilitating the transference of IDIBAPS research to clinicians, patients, and new health professionals in training.
The IBD Unit combines clinicians and investigators from the Hospital Clinic of Barcelona with researchers at IDIBAPS, and serves the metropolitan area of Barcelona, Spain. The IBD Unit is a major referral center for IBD care and research both within Spain and abroad.
The IBD Unit concentrates its research activities on aspects of pathophysiology, diagnosis and treatment of IBD. Specifically, our focus is upon discovering mechanisms bearing direct therapeutic implications. Thus, projects are directed towards the characterization of differential patterns of immune response in early and late CD, which may lead to personalized treatment options based on immune characteristics, and on the identification of molecular factors that maintain remission in these inflammatory disorders. In the area of diagnostics the group is heading initiatives on the use of magnetic resonance imaging for the evaluation of inflammatory lesions in the intestine. In the area of therapeutics the main focus of the group is the development of innovative forms of cell therapies for human IBD, including the use of hematopoietic stem cells, tolerogenic dendritic cells, and epithelial stem cells.
Our research group possesses the know-how for characterizing the mechanistic aspects of drug response in humans and in experimental models of IBD, using a variety of approaches including gene expression microarray studies, tissue and cell cultures, flow cytometry, cell-labeled magnetic resonance studies, conventional endoscopy and endomicroscopy. Moreover, our group has developed the methodology for producing clinical-grade cell products, such as those based on various types of immune cells, for treating IBD patients.